MedTrace Logo

Targeted Retreatment of COPD Exacerbations

NCT02300220 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2021-03-08

Study results available
· View outcomes & findings →

Summary

This study investigates the effects of targeted re-treatment of patients who do not recover from an exacerbation of COPD. Half of the patients will receive ciprofloxacin while the other half will receive a placebo.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Ciprofloxacin

500 mg, twice daily for 1 week (oral)

DRUG

Placebo

One capsule, twice daily for 1 week

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Wisia Wedzicha, Professor · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-05
Primary Completion
2019-01-22
Completion
2019-01-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02300220 on ClinicalTrials.gov